In a special episode of Dementia Matters, Drs. Cynthia Carlsson and Sterling Johnson join the podcast to discuss what they know from lecanemab’s clinical trials following the U.S. Food and Drug Administration’s (FDA) accelerated approval, granted on January 6, 2023.
Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, and Sterling Johnson, PhD, leader, Wisconsin Registry for Alzheimer’s Prevention (WRAP), associate director, Wisconsin Alzheimer’s Disease Research Center and Wisconsin Alzheimer’s Institute
Disclaimers: The statements from Drs. Nathaniel Chin, Cynthia Carlsson and Sterling Johnson do not reflect the opinions of the University of Wisconsin-Madison, UW Health or the Veterans Affairs Healthcare System.
The University of Wisconsin-Madison is one of 100 locations worldwide that are a part of the AHEAD study and one of approximately 63 sites across North America that are a part of the A4 study. Both are clinical studies of the investigational treatment lecanemab in people who may be at risk for memory problems. Dr. Carlsson serves as the principal investigator for the AHEAD and A4 studies at UW-Madison, and Drs. Chin and Johnson serve on the study teams. The AHEAD study is funded by the National Institutes of Health (NIH), in partnership with the pharmaceutical company Eisai, and is being conducted by the NIH-funded Alzheimer’s Clinical Trial Consortium (ACTC). The A4 study is funded by the National Institute on Aging (NIA), NIH, Eli Lilly and Company, and several philanthropic organizations. Read more about the AHEAD and A4 studies in the episode description.
Dementia Matters and Drs. Chin, Carlsson and Johnson receive funding from the National Institute on Aging (NIA) and the National Institutes of Health (NIH). Dr. Johnson has served on advisory boards for Roche Diagnostics, Prothena, Merck and Eisai in the past two years. He receives research funding to the University of Wisconsin from Cerveau Technologies.
Show Notes
In a previous episode of Dementia Matters, Dr. Chin gave a brief overview of lecanemab’s clinical trials. Listen to it on Spotify, Apple Podcasts, our website, or wherever you listen: www.adrc.wisc.edu/dementia-ma...
Read more about the AHEAD study and A4 study at their respective websites: www.aheadstudy.org/, a4study.org/
Connect with us
Find transcripts and more at our website: www.adrc.wisc.edu/dementia-ma...
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter: / wisconsinadrc , / wisconsinadrc
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter: www.adrc.wisc.edu/newsletter